Outsourcing Pharma
AUGUST 17, 2023
BioPharma Reporter and Outsourcing Pharma presents its latest round-up of the movers and shakers in the pharma industry. From Karuna Therapeutics to IO Biotech, we break down the key changes on the pharmaceutical job ladder.
STAT
AUGUST 17, 2023
The health care industry didn’t just provide a safe haven for jittery stock investors in 2022, a year defined by inflation and higher interest rates. It also provided a stable stream of wealth for top executives, who collectively pocketed billions of dollars in what was otherwise a rough patch for the economy. By almost every measure, 2022 was a bad year for the stock market.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmaVoice
AUGUST 17, 2023
The pharma giant’s head of immuno-oncology is now charging toward the next step in the cancer fight with long-term survival and precision.
ALiEM - Pharm Pearls
AUGUST 18, 2023
A middle-aged man with a past medical history of hypertension and tobacco use disorder presented to the Emergency Department after evaluation by an ophthalmologist. He complained of ten days of a right-sided headache and three days of diplopia. He denied eye pain, pain with eye movements, photophobia, and vision loss. Physical Exam Vitals : Temp 98.4 °F (36.9 °C); BP 122/72; Pulse 90; Resp 16; SpO2 100% Neuro : Ptosis, “down and out” deviation and pupil dilation of the right eye were noted.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
BioPharma Dive
AUGUST 15, 2023
More than a dozen startups have joined a few publicly traded biotechs and larger pharmaceutical firms in what’s become one of the most competitive areas in drug research.
STAT
AUGUST 17, 2023
When someone says the word embryo, what do you think of? Probably that picture you’ve seen a thousand times on a thousand different news articles: a translucent orb swelling with cytoplasm being prodded by a microinjection needle under the light of a microscope. The mainstreaming of IVF, or in vitro fertilization, has familiarized new generations of people with what the earliest stages of human development entails.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
The Thyroid Pharmacist
AUGUST 18, 2023
I love the concept of using food as medicine — or as I like to call it, food pharmacology. I became a pharmacist because I was interested in the effects that different substances have on human physiology. Medications are an obvious example of how tiny substances can produce a tremendous change in the human body, but what’s even more intriguing to me is the profound effect that foods and natural substances can have on the body.
BioPharma Dive
AUGUST 18, 2023
BSCA has kicked CVS Caremark, the largest pharmacy benefit manager in the country, to the curb and is electing to carve out various pharmacy functions with companies like Amazon instead.
STAT
AUGUST 17, 2023
A South African court ruled the government must disclose contracts signed with pharmaceutical companies for Covid-19 vaccines, a victory for advocates who alleged that authorities may have overpaid for the shots and that the lack of transparency masked pharmaceutical profits at the public’s expense. At issue are contracts signed by the South African government with several companies — including Johnson & Johnson and Pfizer — that provided millions of Covid-19 vaccines du
PharmaVoice
AUGUST 15, 2023
Drugs like the buzzy Ozempic are high on consumers’ radar — but lofty barriers to access remain.
Advertisement
Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.
Pharmacy Joe
AUGUST 16, 2023
In this episode, I’ll discuss the pharmacist’s role in predicting the need for intubation. Episode 844: Why A Pharmacist Should Learn to Predict the Need for Intubation Subscribe on iTunes , Android , or Stitcher Because of how drug delivery systems are set up in most US hospitals with medications stored in automated dispensing cabinets, there can be a considerable delay between the time a physician makes a decision to intubate a patient until the time the team is ready with medications to
BioPharma Dive
AUGUST 17, 2023
A combination of Trodelvy and Merck’s Keytruda appears active against lung tumors, but has a high bar to clear and faces competition from AstraZeneca and Daiichi Sankyo.
STAT
AUGUST 18, 2023
It was Thanksgiving 2021, and Michael Young was at Target buying a turkey baster. “I’m in the parking lot, and my chest starts to feel like somebody’s sitting on me,” Young recounted. But he didn’t think too much of it and waited until February to tell the doctor about these on-and-off chest pains. “8:30 a.m.
PharmaVoice
AUGUST 18, 2023
With Flagship and Pfizer’s newly announced partnership to find the next big blockbuster, we’re examining some of the VC fund’s biggest successes and failures to date.
Speaker: Joe Sharpe and James Carlson
Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.
European Pharmaceutical Review
AUGUST 16, 2023
Sandoz has announced positive results from the MYLIGHT Phase III study for its biosimilar aflibercept, for patients living with wet macular degeneration. The confirmatory efficacy and safety study ( NCT04864834 ) demonstrated therapeutic equivalence between the biosimilar aflibercept and the reference biologic, Eylea®. The study met its primary efficacy endpoint, showing therapeutic equivalence in mean change of best corrected visual acuity (BCVA) from baseline to week 8 between the biosimilar a
PharmaTech
AUGUST 16, 2023
FDA granted accelerated approval to Elrexfio (elranatamab-bcmm) for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy.
STAT
AUGUST 16, 2023
The nation’s health faces a dual threat — one anticipated, the other, self-inflicted. Covid-19 has not gone away; the Centers for Disease Control and Prevention reports that infections are showing signs of a late summer wave. The new strain, EG.5 , spreads easily and is more resistant to neutralizing antibodies but does not, to date, seem to be more virulent.
BioPharma Dive
AUGUST 14, 2023
Elrexfio is the third bispecific antibody cleared to treat the blood cancer, and will compete with other therapies that target the “BCMA” protein on myeloma cells.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
European Pharmaceutical Review
AUGUST 17, 2023
The National Institutes of Health (NIH) has chosen contract development, and manufacturing organisation (CDMO) Exothera SA to develop the manufacturing process for its intranasal vaccine against SARS-CoV-2 coronavirus to treat COVID-19. As an alternative drug delivery method to traditional injected vaccines, live, replicating, intranasal vaccines have potential for effectively interrupting transmission of COVID-19 by inducing the development of immunity in the respiratory tract.
PharmExec
AUGUST 15, 2023
Bridget Seay of epocrates delves into drug launches in a digital-forward market, exploring how pharmaceutical companies can navigate complex patient journeys, strike a balance between traditional and digital marketing tactics, and ethically engage with healthcare professionals and empowered patients amidst ever-changing regulations.
STAT
AUGUST 15, 2023
Every year, doctors get better tools to fight cancer. Engineered cancer-killing cells, immunotherapies, targeted drugs, and more are helping clinicians cure more patients. Increasingly, though, oncologists are trying to use less radiation, long one of the main pillars of cancer therapy. In some cases, they are even keeping certain patients with low-risk tumors off radiation entirely.
BioPharma Dive
AUGUST 16, 2023
The decision stands in contrast to the agency’s plans for a would-be rival gene editing treatment from Vertex Pharmaceuticals and CRISPR Therapeutics that is also under a regulatory review.
Advertisement
Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.
European Pharmaceutical Review
AUGUST 15, 2023
CPHI, the global pharmaceutical event that spans the entire supply chain from ingredients and finished dosages to machinery, bio, and packaging will return to Fiera Milano (Rho) in 2024. The exhibition, which will take place from 8-10 October 2024, is being hosted in Milan for the second time in three years in recognition of the massive pharmaceutical ingredients and manufacturing industry in the region.
Express Pharma
AUGUST 13, 2023
Mankind Pharma organised an organ donation drive in collaboration with the National Organ and Tissue Transplant Organisation (NOTTO) and prominent medical experts. The event featured a live panel discussion between Dr Sandeep Guleria, Senior Consultant and Transplant Surgeon at Indraprastha Hospital and Apollo Hospital; Dr Subhash Gupta, Chairman of the Centre for Liver & Biliary Sciences, specialising in Liver Transplant and Biliary Sciences, along with Robotic Surgery at Max Super Special
STAT
AUGUST 15, 2023
As Bristol Myers Squibb works to build its treatment for a heart condition that can cause difficulty breathing into a blockbuster drug, it’s propped up an algorithm designed to help find more people who are affected. The algorithm, called Viz HCM and developed by Viz.ai, earlier this month received clearance from the Food and Drug Administration.
BioPharma Dive
AUGUST 14, 2023
Stephen Apps discusses how technology can help improve the speed and quality of clinical research and why a dedicated, cross-functional approach is needed to maximize its value for smaller biotechs.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
European Pharmaceutical Review
AUGUST 14, 2023
Eli Lilly and Company has completed acquisition of two biopharmaceutical companies – Versanis Bio and Sigilon Therapeutics – and their lead assets focused on obesity and diabetes. Lilly announced the successful completion of its acquisition of clinical-stage Versanis Bio and its lead asset bimagrumab, an anti-obesity medicine. Under the terms of the deal – first announced in July – Versanis shareholders could receive up to $1.925 billion in cash, inclusive of the upfront payment and subs
PharmaState Academy
AUGUST 18, 2023
???????????: To be awarded with 3CPhE (Continuing Pharma Education) points. Registrations Open Limited Seats Interest Form For Next Batch We limit the number of participants in a batch so that high-quality interactive learning can happen. In case you have missed this batch, you can fill out the Interest form for the next batch. We will send you the information, once the registrations open for the next batch.
STAT
AUGUST 14, 2023
Shares of Apellis Pharmaceuticals are rebounding, driven by a growing belief among some investors that the serious safety issue that has derailed Syfovre, the company’s eye disease treatment, is receding. Declaring the crisis over is premature, but that could change with more uneventful weeks. Apellis has been a takeout target before, and may be again, at an acquisition price nearly twice its current market value.
FDA Law Blog: Biosimilars
AUGUST 16, 2023
By Douglas B. Farquhar — Francis Godwin, Director of the Office of Manufacturing Quality of the Office of Compliance at FDA’s Center for Drug Evaluation and Research provided useful information (presentation attached here ) Tuesday at the GMP by the Sea Conference. He talked about regulatory discretion being exercised for drug manufacturing facilities with serious compliance problems, about how firms should respond to FDA inspectional observations, and about an upcoming guidance that will be of
European Pharmaceutical Review
AUGUST 14, 2023
Swedish pharmaceutical company Vicore Pharma is developing treatments for diseases where the angiotensin II type 2 receptor (AT2R) has a central role in stopping and reversing disease pathology and where there is a large unmet medical need. The company’s lead candidate, C21, is an angiotensin II type 2 receptor agonist (ATRAG). It represents a new class of drugs capable of reducing pulmonary inflammation, proliferation, fibrosis, and vasculopathy.
Expert insights. Personalized for you.
89 
Let's personalize your content